Interferon-based therapy reduces risk of stroke in chronic hepatitis C patients: A population-based cohort study in Taiwan

Alimentary Pharmacology and Therapeutics

Volumn 38, Issue 4, 2013, Pages 415-423

  Hsu, C S ^a,b   Kao, J H ^c   Chao, Y C ^a,b   Lin, H H ^a,b   Fan, Y C ^a   Huang, C J ^a,b,d   Tsai, P S ^e,f  

^a BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^b TZU CHI UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^e TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^f TAIPEI MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; INTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B;

ADULT; AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK REDUCTION; TAIWAN;

ADULT; AGED; ANTIVIRAL AGENTS; COHORT STUDIES; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PROPORTIONAL HAZARDS MODELS; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; RISK FACTORS; STROKE; TAIWAN; YOUNG ADULT;

EID: 84880296165     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12391     Document Type: Article

References (33)

1. Kao JH, Chen DS,. Transmission of hepatitis C virus in Asia: past and present perspectives. J Gastroenterol Hepatol 2000; 15 (Suppl.): E91-6.
2. Chen DS, Hepatitis C,. virus in chronic liver disease and hepatocellular carcinoma in Taiwan. Princess Takamatsu Symp 1995; 25: 27-32.
3. Galossi A, Guarisco R, Bellis L, Puoti C,. Extrahepatic manifestations of chronic HCV infection. J Gastrointestin Liver Dis 2007; 16: 65-73.
4. Hsu CS, Kao JH,. Hepatitis C infection and metabolic syndrome. J Formos Med Assoc 2010; 109: 403-7.
5. Shaheen M, Echeverry D, Oblad MG, Montoya MI, Teklehaimanot S, Akhtar AJ,. Hepatitis C, metabolic syndrome, and inflammatory markers: results from the Third National Health and Nutrition Examination Survey [NHANES III]. Diabetes Res Clin Pract 2007; 75: 320-6.
6. Hsu CS, Liu CJ, Liu CH, et al,. Metabolic profiles in patients with chronic hepatitis C: a case-control study. Hepatol Int 2008; 2: 250-7.
7. Mehta SH, Brancati FL, Sulkowski MS, Strathdee SA, Szklo M, Thomas DL,. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med 2000; 133: 592-9.
8. Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G,. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001; 33: 1358-64.
9. Grundy SM, Hansen B, Smith SC Jr, Cleeman JI, Kahn RA,. Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. Circulation 2004; 109: 551-6.
10. Hsu CS, Liu CJ, Liu CH, et al,. High hepatitis C viral load is associated with insulin resistance in patients with chronic hepatitis C. Liver Int 2008; 28: 271-7.
11. Ishizaka N, Ishizaka Y, Takahashi E, et al,. Association between hepatitis C virus seropositivity, carotid-artery plaque, and intima-media thickening. Lancet 2002; 359: 133-5.
12. Aslam F, Alam M, Lakkis NM,. Hepatitis C and carotid atherosclerosis: a retrospective analysis. Atherosclerosis 2010; 209: 340-3.
13. Fukui M, Kitagawa Y, Nakamura N, Yoshikawa T,. Hepatitis C virus and atherosclerosis in patients with type 2 diabetes. JAMA 2003; 289: 1245-6.
14. Freiberg MS, Cheng DM, Kraemer KL, Saitz R, Kuller LH, Samet JH,. The association between hepatitis C infection and prevalent cardiovascular disease among HIV-infected individuals. AIDS 2007; 21: 193-7.
15. Lee MH, Yang HI, Wang CH, et al,. Hepatitis C virus infection and increased risk of cerebrovascular disease. Stroke 2010; 41: 2894-900.
16. Liao CC, Su TC, Sung FC, Chou WH, Chen TL,. Does hepatitis C virus infection increase risk for stroke? A population-based cohort study. PLoS One 2012; 7: e31527.
17. Ghany MG, Strader DB, Thomas DL, Seeff LB,. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-74.
18. EASL. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011; 55: 245-64.
19. McCaughan GW, Omata M, Amarapurkar D, et al,. Asian Pacific Association for the Study of the Liver consensus statements on the diagnosis, management and treatment of hepatitis C virus infection. J Gastroenterol Hepatol 2007; 22: 615-33.
20. National Institutes of Health. NIH Consensus Statement on Management of Hepatitis C: 2002. NIH Consens State Sci Statements 2002; 19: 1-46.
21. Kawaguchi T, Ide T, Taniguchi E, et al,. Clearance of HCV improves insulin resistance, beta-cell function, and hepatic expression of insulin receptor substrate 1 and 2. Am J Gastroenterol 2007; 102: 570-6.
22. Romero-Gomez M, Fernandez-Rodriguez CM, Andrade RJ, et al,. Effect of sustained virological response to treatment on the incidence of abnormal glucose values in chronic hepatitis C. J Hepatol 2008; 48: 721-7.
23. Butt AA, Khan UA, Shaikh OS, et al,. Rates of HCV treatment eligibility among HCV-monoinfected and HCV/HIV-coinfected patients in tertiary care referral centers. HIV Clin Trials 2009; 10: 25-32.
24. Hsu CS, Hsu SJ, Chen HC, et al,. Association of IL28B gene variations with mathematical modeling of viral kinetics in chronic hepatitis C patients with IFN plus ribavirin therapy. Proc Natl Acad Sci USA 2011; 108: 3719-24.
25. Lee SD, Yu ML, Cheng PN, et al,. Comparison of a 6-month course peginterferon alpha-2b plus ribavirin and interferon alpha-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan. J Viral Hepat 2005; 12: 283-91.
26. Kao JH, Chen PJ, Lai MY, et al,. Genotypes of hepatitis C virus in Taiwan and the progression of liver disease. J Clin Gastroenterol 1995; 21: 233-7.
27. Liu CH, Liu CJ, Lin CL, et al,. Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial. Clin Infect Dis 2008; 47: 1260-9.
28. Yu ML, Dai CY, Huang JF, et al,. A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C. Gut 2007; 56: 553-9.
29. Younossi Z, Kallman J, Kincaid J,. The effects of HCV infection and management on health-related quality of life. Hepatology 2007; 45: 806-16.
30. Saposnik G, Goodman SG, Leiter LA, et al,. Applying the evidence: do patients with stroke, coronary artery disease, or both achieve similar treatment goals? Stroke 2009; 40: 1417-24.
31. Forton DM, Allsop JM, Main J, Foster GR, Thomas HC, Taylor-Robinson SD,. Evidence for a cerebral effect of the hepatitis C virus. Lancet 2001; 358: 38-9.
32. Lee MH, Yang HI, Wang CH, et al,. Hepatitis C virus infection and increased risk of cerebrovascular disease. Stroke 2010; 41: 2894-900.
33. Cheng CL, Kao YH, Lin SJ, Lee CH, Lai ML,. Validation of the National Health Insurance Research Database with ischemic stroke cases in Taiwan. Pharmacoepidemiol Drug Saf 2011; 20: 236-42.